Hussein D Aoun1, Peter J Littrup2, Mohamed Jaber3, Fatima Memon3, Barbara Adam4, Mark Krycia3, Matthew Prus4, Elisabeth Heath5, Edson Pontes6. 1. Imaging Division, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. Electronic address: aounh@karmanos.org. 2. Department of Diagnostic Imaging, Brown University, Rhode Island Hospital, Providence, Rhode Island. 3. Department of Radiology, Wayne State Medical School, Detroit, Michigan. 4. Imaging Division, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 5. Division of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 6. Division of Urology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Abstract
PURPOSE: To retrospectively assess long-term outcomes of percutaneous renal cryoablation, including factors affecting complications and local recurrence rates. MATERIALS AND METHODS: A total of 357 computed tomographic (CT) fluoroscopy-guided percutaneous cryoablation procedures were performed for 382 masses in 302 outpatients; 347 were biopsy-proven renal-cell carcinoma (RCC) or Bosniak category > III masses (n = 28). Benign pathologic conditions (n = 18) or metastatic non-RCC disease (n = 17) were included to analyze procedural complication rate, but recurrence rates, tumor staging, and nephrometry score were limited to RCCs. The average tumor diameter was 2.9 cm (range, 1-10.3 cm), and median nephrometry score for RCC was 8 (mean, 7.4). Protection of adjacent vital structures was performed in 34% of procedures (n = 121), and ureteral stent placement was performed for 9.2% (n = 33). All major complications were graded per surgical Clavien-Dindo criteria. RESULTS: The average CT-visible cryoablation zone diameter was 5 cm (range, 2.5-10.5 cm). Grade ≥ 3 complications occurred in 2.8% of procedures (n = 10), and appeared related to only high nephrometry scores (P = .0086) and larger tumors (P = .0034). No significant changes in renal function before and after the procedure were noted (P = .18). At a mean follow-up of 31.8 months, the local tumor recurrence rate was 3.2% (11 of 347) for RCC, and no significant difference was noted between tumors larger or smaller than 3 cm (P = .15). The difference reached significance only among the small number of stage ≥ T2 RCC tumors (P = .0039). CONCLUSIONS: Long-term follow-up of percutaneous renal cryoablation demonstrates low recurrence rates with preserved renal function, even for patients with high nephrometry scores and body mass index, assuming thorough cytotoxic technique and protection measures.
PURPOSE: To retrospectively assess long-term outcomes of percutaneous renal cryoablation, including factors affecting complications and local recurrence rates. MATERIALS AND METHODS: A total of 357 computed tomographic (CT) fluoroscopy-guided percutaneous cryoablation procedures were performed for 382 masses in 302 outpatients; 347 were biopsy-proven renal-cell carcinoma (RCC) or Bosniak category > III masses (n = 28). Benign pathologic conditions (n = 18) or metastatic non-RCC disease (n = 17) were included to analyze procedural complication rate, but recurrence rates, tumor staging, and nephrometry score were limited to RCCs. The average tumor diameter was 2.9 cm (range, 1-10.3 cm), and median nephrometry score for RCC was 8 (mean, 7.4). Protection of adjacent vital structures was performed in 34% of procedures (n = 121), and ureteral stent placement was performed for 9.2% (n = 33). All major complications were graded per surgical Clavien-Dindo criteria. RESULTS: The average CT-visible cryoablation zone diameter was 5 cm (range, 2.5-10.5 cm). Grade ≥ 3 complications occurred in 2.8% of procedures (n = 10), and appeared related to only high nephrometry scores (P = .0086) and larger tumors (P = .0034). No significant changes in renal function before and after the procedure were noted (P = .18). At a mean follow-up of 31.8 months, the local tumor recurrence rate was 3.2% (11 of 347) for RCC, and no significant difference was noted between tumors larger or smaller than 3 cm (P = .15). The difference reached significance only among the small number of stage ≥ T2 RCC tumors (P = .0039). CONCLUSIONS: Long-term follow-up of percutaneous renal cryoablation demonstrates low recurrence rates with preserved renal function, even for patients with high nephrometry scores and body mass index, assuming thorough cytotoxic technique and protection measures.
Authors: Sagar Rohitkumar Patel; Sean Francois; Tiagpaul Bhamber; Holt Evans; Kris Gaston; Stephen B Riggs; Chris Teigland; Peter E Clark; Ornob P Roy Journal: Arab J Urol Date: 2020-03-23
Authors: Matthew Seager; Shankar Kumar; Emma Lim; Graham Munneke; Steve Bandula; Miles Walkden Journal: Br J Radiol Date: 2020-09-22 Impact factor: 3.039
Authors: Tim J van Oostenbrugge; Jan Heidkamp; Michael Moche; Phil Weir; Panchatcharam Mariappan; Ronan Flanigan; Mika Pollari; Stephen Payne; Marina Kolesnik; Sjoerd F M Jenniskens; Jurgen J Fütterer Journal: Cardiovasc Intervent Radiol Date: 2020-09-15 Impact factor: 2.740